Outcome of an elective readmission policy in patients receiving acute myeloid leukaemia consolidation therapy and implications for an outpatient management programme.
acute myeloid leukaemia
consolidation chemotherapy
neutropenic fever
outpatient
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
03
11
2022
accepted:
14
05
2023
medline:
22
8
2023
pubmed:
21
8
2023
entrez:
20
8
2023
Statut:
ppublish
Résumé
Safe outpatient management of acute leukaemia consolidation cycles may enable substantial savings in admission costs. Safety involves the prompt administration of antibiotics in patients with neutropenic fever. Our unit in a metropolitan tertiary referral hospital analysed a cohort of patients spanning a 10-year period, with two key observations: (i) a high proportion of patients living a substantial distance from hospital and (ii) the high incidence and generally prompt onset of fever after severe neutropenia, suggesting this broad applicability of this approach is unfeasible without addressing travel issues and potentially reducing and/or delaying neutropenic fever with prophylactic antibiotics.
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1492-1496Informations de copyright
© 2023 Royal Australasian College of Physicians.
Références
Halpern A, Walter RB, Estey E. Outpatient induction and consolidation care strategies in acute myeloid leukaemia. Curr Opin Hematol 2019; 26: 65-70.
Walker S, Grigg S, Kirkpatrick C, Urbancic K, Cohen E, Grigg A et al. Nurse-initiated pre-prescribed antibiotic orders to facilitate prompt and appropriate antibiotic administration in febrile neutropenia. Support Care Cancer 2020; 28: 4337-4343.
Slavin MA, Lingaratnam S, Mileshkin L, Booth DL, Cain MJ, Ritchie DS et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41: 102-109.
Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect 2018; 76: 20-37.
Gafter-Gvili PM, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 2006; 59: 5-22.
Pepin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
Hakki M, Humphries R, Hemerajata P, Tallman G, Shields R, Mettus R et al. Fluoroquinolone prophylaxis selects for meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis 2019; 12: 2045-2052.
Aw A, Sabloff M, Sheppard D, Allan D, Atkins H, Bence-Bruckler I et al. Evaluation of an outpatient model for treatment of acute myeloid leukemia. J Hematol 2016; 5: 1-7.
Godwin J, Kopecky K, Head D, Willman C, Leith C, Hynes H et al. A double-blind placebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukaemia: a Southwest Oncology Group Study (9031). Blood 1998; 91: 3607-3615.